Clinical Trials Register

Trials with a EudraCT protocol (340)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

340 result(s) found for: Uterine Cancer. Displaying page 7 of 17.

EudraCT Number: 2017-004690-14

Sponsor Protocol Number: NA

Start Date*: 2021-01-12

Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

Full Title: RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)

Medical condition: Ovarian cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026311	Malignant neoplasm of ovary and other uterine adnexa	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061535	Ovarian neoplasm	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061344	Peritoneal neoplasm	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2007-001731-55

Sponsor Protocol Number: 106636

Start Date*: 2007-08-09

Sponsor Name:GlaxoSmithKline Biologicals

Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p...

Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	100000004864	10008230	Cervix neoplasms malignant	HLT

Population Age: Adolescents, Under 18

Gender: Male, Female

Trial protocol: FI (Completed)

Trial results: View results

EudraCT Number: 2011-003062-32

Sponsor Protocol Number: B1271004

Start Date*: 2011-12-20

Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Full Title: A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER

Medical condition: RECURRENT ENDOMETRIAL CANCER

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014736	Endometrial cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: SK (Prematurely Ended) ES (Completed) PL (Completed) DE (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2009-016707-30

Sponsor Protocol Number: XL147-201

Start Date*: 2010-05-10

Sponsor Name:Sanofi-aventis US Inc.

Full Title: A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma

Medical condition: The purpose of this study is to assess the efficacy and safety of XL147 in subjects with advanced or recurrent EC.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014747	Endometrial carcinoma recurrent	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Prematurely Ended) FR (Completed)

Trial results: View results

EudraCT Number: 2021-000135-31	Sponsor Protocol Number: TABENETOC	Start Date*: 2022-01-12
Sponsor Name:Region Östergötland
Full Title: The Effect of tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy – A randomized pilot study
Medical condition: Epithelial ovarian cancer
Disease:
Population Age: Adults, Elderly		Gender: Female
Trial protocol: SE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2009-017671-22

Sponsor Protocol Number: E7389-G000-398

Start Date*: 2010-07-15

Sponsor Name:Eisai Limited

Full Title: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies

Medical condition: Advanced and/or metastatic breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10006198	Breast cancer recurrent	LLT
	12.1		10027475	Metastatic breast cancer	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: BE (Completed)

Trial results: View results

EudraCT Number: 2009-011382-80	Sponsor Protocol Number:	Start Date*: 2009-06-22
Sponsor Name:Nottingham University Hospital
Full Title: Intravenous Iron: biomarkers and treatment strategies in anaemic Colorectal cancer patients.
Medical condition: Anaemia (specifically related to surgical pathology)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results

EudraCT Number: 2005-004280-31	Sponsor Protocol Number: 04/280507	Start Date*: 2006-02-02
Sponsor Name:University of Dundee
Full Title: Hyperthermic Intraperitoneal Chemotherapy - Gastric Cancer
Medical condition: Gastric Cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results

EudraCT Number: 2011-000299-33

Sponsor Protocol Number: AGO-GYN8

Start Date*: Information not available in EudraCT

Sponsor Name:AGO Research GmbH

Full Title: Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma

Medical condition: platinum-refractory ovarian carcinoma or advanced endometrial carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	15.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT
	15.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066697	Ovarian cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Completed)

Trial results: (No results available)

EudraCT Number: 2020-002727-11

Sponsor Protocol Number: CRO-2020-043

Start Date*: 2023-08-02

Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO

Full Title: Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: Multicentric Phase II Study.

Medical condition: Patients with locally advanced, potentially resectable, Middle-Distal Rectal Carcinoma, stage T3c-d N1-2, MRF + or T4N0-2, EMVI - / + (High-Risk)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10007464	Carcinoma rectum	LLT
	20.0	100000004864	10038052	Rectal carcinoma	LLT
	20.0	100000004864	10007446	Carcinoma of rectum	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2012-001334-33

Sponsor Protocol Number: HPV-003

Start Date*: 2013-01-09

Sponsor Name:Inovio Pharmaceuticals, Inc.

Full Title: PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA®-5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR ...

Medical condition: Cervical Intraepithelial Neoplasia (CIN) 2/3 or 3

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10038604 - Reproductive system and breast disorders	10008263	Cervical dysplasia	PT

Population Age: Adults

Gender: Female

Trial protocol: EE (Completed)

Trial results: View results

EudraCT Number: 2014-004721-40

Sponsor Protocol Number: HPV-EU-001

Start Date*: 2015-04-22

Sponsor Name:Genexine, Inc

Full Title: A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularl...

Medical condition: Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10038604 - Reproductive system and breast disorders	10008263	Cervical dysplasia	PT

Population Age: Adults

Gender: Female

Trial protocol: EE (Completed)

Trial results: (No results available)

EudraCT Number: 2013-003503-19

Sponsor Protocol Number: MGN1703-C03

Start Date*: 2014-01-28

Sponsor Name:Mologen AG

Full Title: Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Medical condition: Small Cell Lung Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041068	Small cell lung cancer extensive stage	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) AT (Completed) DE (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2007-007177-23

Sponsor Protocol Number: Mo19051

Start Date*: 2008-11-12

Sponsor Name:U.Z. Gasthuisberg

Full Title: A randomized phase II of bevacizumab, capecitabine and radiation therapy with or without oxaliplatin in the preoperative treatment of locally advanced rectal cancer

Medical condition: locally advanced rectal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10038049	Rectal cancer stage II	LLT
	9.1		10038050	Rectal cancer stage III	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed)

Trial results: View results

EudraCT Number: 2008-000879-26

Sponsor Protocol Number: 311602-Amendment 1

Start Date*: 2008-08-07

Sponsor Name:Bayer Schering Pharma AG

Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.

Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10066697	Ovarian cancer recurrent	LLT
	9.1		10036909	Prostate cancer metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)

Trial results: View results

EudraCT Number: 2019-004895-21	Sponsor Protocol Number: WO42017	Start Date*: 2020-06-01
Sponsor Name:F. Hoffmann-La Roche Ltd
Full Title: A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER.
Medical condition: Cervical cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
Trial results: View results

EudraCT Number: 2017-002323-25

Sponsor Protocol Number: AA1720

Start Date*: 2017-09-22

Sponsor Name:Center for cancer immune therapy

Full Title: Adoptive cell therapy across cancer diagnoses

Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055099	Ocular cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055100	Otic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055108	Thymic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050017	Lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059514	Small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055104	Pharyngeal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055105	Sinus cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055096	Anal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10053548	Gastrointestinal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055097	Rectal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055114	Colon cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10052358	Colorectal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055098	Oral cavity cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055109	Tongue cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055102	Oesophageal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050018	Renal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046394	Ureteric cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046433	Urethral cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055115	Skin cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055101	Bone cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055095	Adrenal gland cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055106	Pituitary cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055107	Thyroid cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055113	Breast cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055111	Biliary cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066879	Gallbladder cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055110	Hepatic cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055094	Cervix cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014734	Endometrial cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016182	Fallopian tube cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033158	Ovarian epithelial cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10046887	Vaginal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10047742	Vulval cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10036909	Prostate cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10055103	Testicular cancer metastatic	PT
	20.0	100000016906	10033605	Pancreatic cancer metastatic	LLT
	20.0	100000016840	10023183	Jejunum cancer metastatic	LLT
	20.0	100000016840	10013816	Duodenal cancer metastatic	LLT
	20.0	100000016840	10023167	Jejunal cancer metastatic	LLT
	20.0	100000017543	10038498	Renal pelvis and ureter transitional cell cancer metastatic	LLT
	20.0	100000017543	10038509	Renal pelvis and ureteric cancer metastatic transitional cell	LLT
	20.0	100000017725	10046377	Ureter cancer metastatic	LLT
	20.0	100000017773	10046420	Urethra cancer metastatic	LLT
	20.0	100000021146	10036947	Prostatic cancer metastatic	LLT
	20.0	100000016931	10062478	Esophageal cancer metastatic	LLT
	20.0	100000143841	10063107	Tubular breast cancer metastatic	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068694	Testicular germ cell cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10068971	Germ cell cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10069728	Rectosigmoid cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10069730	Large cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070902	Laryngeal cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071540	Head and neck cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10072792	Tonsil cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10079104	Nasopharyngeal cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2011-001382-40

Sponsor Protocol Number: Metform01

Start Date*: 2011-09-09

Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust

Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study

Medical condition: Endometrial carcinoma or hyperplasia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2020-001970-31

Sponsor Protocol Number: HYBRID_ENDONODE

Start Date*: 2020-08-06

Sponsor Name:Fundació Clínic per a la Recerca Biomèdica

Full Title: Sentinel node in endometrial cancer using hybrid detection ([99mTc] Tc-albumin nanocoloid-ICG). Comparative pilot study between the lymphatic map derived from the cervical versus myometrial puncture.

Medical condition: Patients with endometrial cancer who are going to undergo surgery for the primary tumor and lymph node study using lymphadenectomy and detection of the sentinel node

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: ES (Completed)

Trial results: (No results available)

EudraCT Number: 2017-000607-25

Sponsor Protocol Number: KCP-330-024BGOG-EN5/ENGOT-EN5/SIEND

Start Date*: 2017-11-22

Sponsor Name:Karyopharm Therapeutics Inc.

Full Title: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with advanced endometrial cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014734	Endometrial cancer metastatic	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014736	Endometrial cancer recurrent	PT

Population Age: Adults

Gender: Female

Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) IT (Trial now transitioned) GR (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Uterine Cancer